Assistance Publique Hopitaux De Paris — Sponsor Intelligence | 260 EU Trials

Filter these 260 trials by condition, phase, country and more.

Open in Search →

260 Registered trials

135 Recruiting

57 Completed trials

13 Countries active

348 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 137 Phase II/III: 14 Phase II: 71 Phase I/II: 10 Phase III/IV: 6 Phase IV: 11 Phase I: 4 Phase I (Other): 2 Phase I (FiH): 5

Oversight events:

1 serious breach 12 temporary halts 9 urgent safety measures 2 unexpected events 8 corrective measures across 24 trials

View oversight register →

100%

57 of 57 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Sickle cell disease 3 Cutaneous T-cell lymphoma 2 Ischaemic stroke 2 Acute kidney injury 2 Giant cell arteritis 2 Autism spectrum disorder 2 Atrial fibrillation 1 Paraneoplastic neurological syndrome 1 B-cell lymphoma 1 Progressive multifocal leukoencephalopathy 1 Cardiac arrest 1 Pulmonary sarcoidosis 1

Top IMPs

ALLOGENEIC FAECAL MICROBIOTA, POOLED 10 SODIUM CHLORIDE 7 PLACEBO 6 PREDNISONE 5 ANAKINRA 4 CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS 4 TOCILIZUMAB 4 BARICITINIB 3 COLCHICINE 3 METHOXYFLURANE 99.9% 3 METRONIDAZOLE 3 OBINUTUZUMAB 3

All trials

260 total

MAMI Use of the Methoxyflurane as pain-killer in the prehospital management of Acute Myocardial Infarction Not authorised

2023-507296-21-00 Phase III 1 country METHOXYFLURANE 99.9%
TIC-TAC-SAM « Comparison of two strategies of etoposide initiation in severe sporadic hemophagocytic lymphohistiocytosis in intensive care: … Not authorised

2024-511807-41-00 Phase III 1 country
MOOD - MethOxyflurane analgesia in vasoOcclusive crises of sickle cell Disease Not authorised

2024-518043-38-00 Phase III 1 country METHOXYFLURANE 99.9%
Topical Clobetasol Propionate for Inflammatory Hand osteoarthritis: A randomized trial versus placebo.(PROCLAME) Not authorised

2025-520678-20-00 Phase III 1 country
ANTIMIDIS - Cefazolin mediastinal distribution using microdialysis Not authorised

2025-521988-13-00 Phase IV 1 country
Fecal microbiota transplantation for primary sclerosing cholangitis - randomized study versus sham transplantation (FMT-SCLER). Pending

2023-505469-95-00 Phase II/III 1 country ALLOGENEIC FAECAL MICROBIOTA, POOLED; PLACEBO
Echec-MAT - A combination of antibiotics to improve neonatal mortality and morbidity for pregnancies complicated with previable labour and i… Pending

2023-505500-37-00 Phase III 1 country CEFTRIAXONE SODIUM; CLARITHROMYCIN; METRONIDAZOLE
Efficacy and safety of zoledronate versus placebo on pain at week 12 in pediatric patients with chronic recurrent multifocal osteomyelitis r… Pending

2023-506420-93-00 Phase II 1 country
SCARR : « Allogenic Umbilical Cord Mesenchymal Stromal Cells for the treatment of chronic renal (cABMR) graft rejection » Pending

2023-506598-36-00 Phase II/III 1 country ALLOGENEIC UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLS EX VIVO EXPAN…
Pulse corticosteroids or/and Immunoglobulins to treat fulminant Myocarditis: a double-blind randomized controlled adaptive trial (The CORIUM… Pending

2023-506599-28-01 Phase II 1 country GLUCOSE
In situ injection of anti-angiogenics in patients with brain arteriovenous malformations not eligible for exclusion treatment: phase I trial… Pending

2023-506991-28-00 Phase I (Other) 1 country
CUSHMAH - Benefit of steroidogenesis inhibitors in Mild Cushing syndrome (Mild Autonomous Cortisol Secretion): a randomized trial in patient… Pending

2023-507010-27-00 Phase III 1 country METYRAPONE
MUNC13.4 - A phase I/II Open Label non randomized study, monocentric, single arm, evaluating Safety and Efficacy of Gene Therapy of FHL 3 ca… Pending

2023-507334-24-00 Phase I 1 country MUNC-CD34; MUNC-T3
Randomized control trial comparison between intra-articular infiltrations of PRP, MFAT, and PRP-MFAT in the treatment of symptomatic knee os… Pending

2023-507683-40-00 Phase III 1 country
RASBU-SEPSIS Study: Effects of rasburicase on kidney during sepsis – a randomized, placebo-controlled, double-blind trial Pending

2023-508071-36-00 Phase III 1 country RASBURICASE
Efficacy and tolerance of nicotinamide supplementation during acute kidney injury: a prospective randomized double-blind trial Pending

2023-508664-30-00 Phase III 1 country
Effect of Sildenafil in association to Hypothermia on survival without brain lesions In term Neonates with hypoxic-ischemic Encephalopathy: … Pending

2023-508928-35-00 Phase II/III 1 country SILDENAFIL
AUTOP 2 : Screen-and-treat strategy for vaginal flora abnormalities by molecular biology in pregnant women at high risk of preterm birth: A … Pending

2023-509421-41-03 Phase III 1 country AZITHROMYCIN DIHYDRATE; CLOTRIMAZOLE; DOXYCYCLINE (ANHYDROUS); LIDOCAINE HYDROCH…
Nebulized Amikacine for Ventilator associated gram negative Pneumonia in ECMO veno-arterial patients: A randomized Pilot Study (NAVAP-ECMO) Pending

2023-509722-22-00 Phase II 1 country
Corticoid Therapy in Acute Myocarditis Pending

2024-510602-90-00 Phase III 1 country METHYLPREDNISOLONE; PREDNISONE
APICALE - Cervical facet injection of corticosteroids for the management of cervicobrachialgia : protocol for a randomized pilot study Pending

2024-511790-30-00 Phase III 1 country
TIC-TAC-SAM « Comparison of two strategies of etoposide initiation in severe sporadic hemophagocytic lymphohistiocytosis in intensive care: … Pending

2024-511807-41-01 Phase III 1 country
Efficacy of certolizumab in women with unexplained recurrent implantation failure: a double-blind randomized controlled trial (CERTIFY) Pending

2024-511869-11-00 Phase III 1 country CERTOLIZUMAB PEGOL
Multisite open-label randomized phase II clinical trial in newly diagnosed glioblastoma treated by concurrent TemoRadiation and adjuvant tem… Pending

2024-511880-27-00 Phase II 2 countries PERFLUTREN

Showing 1–24 of 260 trials

← All sponsors A–Z